PATINA trial paved the way for palbociclib-based frontline maintenance regimen
— PATINA trial paved the way for palbociclib-based frontline maintenance regimen
June 24, 2026
• 2 min read
The FDA approved the CDK4/6 inhibitor palbociclib (Ibrance) as part of a first-line maintenance regimen for hormone receptor (HR)-positive/HER2-positive breast cancer.
Approval stipulates use of palbociclib plus trastuzumab -- with or without pertuzumab (Perjeta) -- and endocrine therapy following induction treatment for adults with locally advanced or metastatic disease.
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
Ibrance nabs FDA approval for HR-positive, HER2-positive metastatic breast cancer
Pfizer scores 1st expansion in 7 years for breast cancer blockbuster Ibrance
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
The FDA has approved the first and only cyclin-dependent kinase 4/6 inhibitor for patients with HR-positive metastatic breast…
How data from HER2CLIMB-05 and PATINA are influencing treatment decisions
Treatment with CDK4/6 inhibitor led to nearly 10-month median PFS in placebo-controlled SARC041
It’s been seven years since Pfizer scored an expansion for its breast cancer blockbuster Ibrance, and during that time, the drug…
Novel gedatolisib is currently under review at FDA for wild-type patients
